Study of POISE Supportive Care Model for Adults with Metastatic Non-small Cell Lung Cancer on Targeted Therapy
Led by Massachusetts General Hospital · Updated on 2025-11-24
70
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a supportive care model called POISE for patients with metastatic Non-small Cell Lung Cancer NSCLC who have oncogenic driver mutations and are receiving targeted therapy. This study aims to see if POISE is feasible to deliver, acceptable to patients, and how it affects patients distress about their uncertain future, confidence in managing cancer, and understanding of what to expect.
The POISE intervention includes four 60-minute sessions with specially trained palliative care clinicians who address psychosocial issues and promote health behaviors. Participants in the randomized controlled trial will either receive POISE or continue with usual oncology care, which may include standard palliative care if needed. The study involves an open pilot phase with 10 patients followed by a randomized phase with 60 patients.
Participants will complete three surveys at baseline, 12 weeks, and 20 weeks after enrollment, and undergo chart reviews and an exit interview. Researchers will measure feasibility by enrollment rates and session and survey completions, along with acceptability, emotional coping, prognostic awareness, self-efficacy, and documentation of goals and values over 12 to 20 weeks. The total participation period is about 20 weeks.
CONDITIONS
Brief Title
Patient-centered, Optimal Integration of Survivorship and Palliative Care
Research Team
L
Laura A Petrillo, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
POISE (Brief Survivor‑Palliative Care Support)
Usual care (no additional palliative‑survivorship sessions)
What it is
A short, tailored behavioral intervention of four sessions with trained palliative‑survivorship clinicians for patients on targeted therapy for metastatic NSCLC.
Standard care involving targeted therapy without added palliative‑survivorship sessions.
Role in trial
Investigational behavioral intervention introduced in addition to standard oncologic care.
Control arm receiving standard care with no additional intervention.
Primary use
Test whether integrating survivorship and palliative care sessions is feasible and acceptable.
Represents current standard supportive care for patients receiving targeted therapy.
How it is given
Delivered over four sessions by palliative‑survivorship specialists trained for psychosocial and health behavior support.
Continues usual oncology care without added sessions.
Evidence status
Feasibility outcomes (enrollment and session completion) are being evaluated; efficacy not yet established.
Established standard care in current oncology practice.
Important risks
No safety concerns reported; behavioral sessions generally low risk.
Typical oncology supportive care risks apply.
Important limitations
Pilot study assessing feasibility in a small, selected population; not powered for clinical outcomes.
Usual care may differ by institution and lacks structured palliative‑survivorship support.
Patient impact
Impact on quality of life, emotional coping, and self‑efficacy is being assessed but not yet known.
Represents baseline supportive care without added palliative‑survivorship intervention.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 or older
Current patient at Massachusetts General Hospital Cancer Center
Diagnosed with metastatic NSCLC with oncogenic driver mutation (EGFR, ALK, ROS1, RET) within past 6 months
Receiving targeted therapy
Able to respond in English or Spanish
You will not qualify if you...
Cognitive impairment or serious mental illness limiting ability to consent
Need for urgent palliative care or hospice referral
Pregnant women
Prisoners
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) for eligibility assessment
Outpatient Treatment
Duration - Approximately 12 weeks
Participants receive four 60-minute sessions with a trained palliative care clinician to address psychosocial issues and health-promoting behaviors related to metastatic NSCLC.
4 visits with a palliative care clinician
Follow-up
Duration - Up to 20 weeks post-enrollment
Participants complete questionnaires at baseline, 12 weeks, and 20 weeks post-enrollment, and participate in a semi-structured exit interview. Chart reviews are also conducted.
3 questionnaire timepoints and 1 exit interview
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Evaluating Safety, Tolerability, and Preliminary Effectiveness of Oral VMD-102 in Adults with Advanced Liver Cancer and Other Solid Tumors
Phase 12 Study of Oral TRI-611 in Adults with Advanced ALK-Positive Non-Small Cell Lung Cancer
Phase I Open-Label Study Evaluating Imaging, Safety, and Pharmacokinetics of 68GaGa-DWJ155 in Adults with Advanced Breast and Non-Small Cell Lung Cancers
Phase III Study of UCB4594, a Monoclonal Antibody Targeting HLA-G, Alone and With Other Cancer Treatments in Adults With Advanced Solid Tumors
Study of Ensartinib Treatment in Advanced ALK-Positive Non-Small Cell Lung Cancer
Comparing Virtual Music Therapy and Cognitive Behavioral Therapy to Reduce Anxiety in Cancer Survivors
Randomized Study Comparing Adagrasib Plus Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy for Untreated Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Study of Amivantamab and Olomorasib Combination Therapy to Find Best Dose and Evaluate Safety in Metastatic KRAS G12C Non-Small Cell Lung Cancer
Study of Amivantamab with Lazertinib or Platinum-Based Chemotherapy for EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 2 Open-Label Study of Subcutaneous Amivantamab in Multiple Treatment Regimens for Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Blended palliative and survivorship care intervention (POISE) for patients with metastatic oncogene-driven non-small cell lung cancer: study protocol for a pilot randomised controlled trial.
Heather A Richard, Roshni Sarathy, Dustin J Rabideau...